Oppenheimer Maintains Outperform on Tyra Biosciences, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has maintained an 'Outperform' rating on Tyra Biosciences and raised the price target from $25 to $33.
September 19, 2024 | 11:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reaffirmed its 'Outperform' rating for Tyra Biosciences and increased the price target from $25 to $33, indicating a positive outlook.
The increase in price target from $25 to $33 by Oppenheimer suggests a strong positive outlook for Tyra Biosciences. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100